ADMA BIOLOGICS, INC.
Close on Oct 19, 2026
- Market cap
- $2.55B
- P/E (TTM)
- 15.8
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $124.40M | $0.16 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $114.50M | $0.19 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | During market hours | $139.20M | $0.20 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | During market hours | $134.20M | $0.15 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $122.00M | $0.14 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | $114.80M | $0.11 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | During market hours | $117.50M | $0.46 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $119.80M | $0.15 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | FY2026 | $265.00M to $300.00M | Maintained |
| Adjusted Net Incomenon-GAAP | FY2026 | $170.00M to $200.00M | Maintained |
| total revenue | FY2026 | $530.00M to $560.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Adma Biologics filed with the SEC
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV TM to Include Pediatric Immune
Other events · EX-99.1 to Form 8-K
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
Regulation FD disclosure · EX-99.1 to Form 8-K
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
Material agreement · Agreement terminated · Results of operations · New financial obligation · EX-99.1 to Form 8-K
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Realizing the Potential of Specialty Biologicswith
Regulation FD disclosure · EX-99.1 to Form 8-K
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Realizing the Potential of Specialty Biologicswith
Regulation FD disclosure · EX-99.1 to Form 8-K
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
Other events · EX-99.1 to Form 8-K
ADMA Biologics Realizing the Potential of Specialty Biologicswith
Regulation FD disclosure · EX-99.1 to Form 8-K
ADMA Biologics Announces CFO Transition
Executive or director change · Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
Other events · EX-99.1 to Form 8-K
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking
Regulation FD disclosure · EX-99.1 to Form 8-K
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces FDA Approval for BIVIGAM ® in the Pediatric Patient
Other events · EX-99.1 to Form 8-K
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
ADMA Biologics Announces Amendment to Credit Agreement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
Other events · EX-99.1 to Form 8-K
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023
Results of operations · EX-99.1 to Form 8-K